$30 Million Suboxone Class Action Settlement

Photo Credit: Unsplash | Updated: June 24, 2026

Status Settlement Closed — Checks Mailed distribution checks were mailed April 27, 2026; the June 15, 2026 final cutoff for any adjustments has passed

Settlement Amount $30,000,000 antitrust overcharge claims against Indivior

Class Period December 22, 2011 – August 21, 2023 purchasers of Suboxone or its AB-rated generic equivalents

Proof Required No eligibility was based on qualifying purchases in covered states

Final Update: Checks Mailed, Cutoff Passed

The $30 Million Suboxone antitrust settlement has reached its final stages. Here is where things stand:

• Checks have been mailed. Distribution checks were officially sent to eligible claimants on April 27, 2026. If you submitted a valid claim before the February 2024 deadline, your payment should have already arrived in your mailbox or account.
• The final cutoff has passed. The settlement administrator set a strict deadline of June 15, 2026. After that date, the administrator is no longer accepting or considering any additional documentation, check reissue requests, claim reviews, or adjustments of any kind.

With checks mailed and the June 15, 2026 cutoff passed, there is nothing further for class members to file or submit. For reference only, the official settlement website remains at SuboxAntiTrust.com.

What is the Suboxone Settlement About?

A $30 Million Class Action Lawsuit has been settled over antitrust allegations that led to consumers and patients overpaying for Suboxone, also known as Buprenorphine or Naloxone, as well its "AB-rated" generic equivalent medications. The suboxone class action lawsuit made assertions that Suboxone manufacturers and marketers violated certain state antitrust, consumer protection laws, as well as unjust enrichment laws as indicated in United States law. The class action alleges that Suboxone harmed competition, leading to overpayments made by patients (class action members) for the drug, harming them financially in the process. The defendants in the case, Indivior, have agreed to the $30 Million class action settlement, but have not accepted that they violated any laws.

The class action includes certain States, and periods of time that a purchase must have been made between December 22, 2011 and August 21, 2023. The full list of states is available below. Previously, the Federal Trade Commission (FTC) had returned nearly $60,000,000 to over 50,000 patients, totalling an average payment of $1,139 per patient. The FTC complaint and refund had also alleged that Indivior, Inc., as well as Reckitt Benckiser Group, had colluded to thwart competition and created artificially high prices for consumers of the Suboxone drug. Reckitt Benckiser and Indivior, Inc. were alleged by the FTC of attempting to prevent consumers from accessing a more affordable generic alternative to Suboxone, a prescription oral medication used to alleviate withdrawal symptoms in individuals recovering from opioid addiction. This alleged action was aimed at preserving their profitable monopoly on the branded drug.

What is Suboxone?

Suboxone is a prescription medication that plays a vital role in the treatment of opioid addiction. Suboxone is a critical medication in the treatment of opioid addiction, helping individuals manage withdrawal symptoms and cravings. It is a combination of two active ingredients: Buprenorphine/naloxone, and Suboxone is sold under this brand name, among other brand names, or generic drugs that are equivalent. Typically, Suboxone is a fixed-dose combination medication that includes buprenorphine and naloxone.

• Buprenorphine This is a partial opioid agonist, meaning it activates the opioid receptors in the brain but to a lesser degree than full opioids like heroin or prescription painkillers. It helps reduce cravings and withdrawal symptoms, making it easier for individuals to transition away from full opioids.

• Naloxone This is an opioid antagonist, which means it blocks the effects of opioids. It's included in Suboxone to deter misuse. If Suboxone is injected or misused intravenously, the Naloxone can trigger withdrawal symptoms, discouraging abuse.

Suboxone is crucial for individuals dealing with opioid addiction because it helps them manage their addiction and withdrawal symptoms, making the process of recovery more manageable. It allows them to stabilize their lives, participate in therapy, and work towards long-term recovery. Suboxone is considered a safer alternative to the opioids people may have been using, reducing the risk of overdose and death, which has been the subject of a mass drug and opioid crisis in the United States for decades now, leading to one of the biggest open class action settlements of all time, a $54 Billion Settlement. Read more about it here, in a class action settlement involving large retailers and pharmacy chains CVS and Walgreens.

Who is the Defendant: Indivior?

Indivior, Inc. is a pharmaceutical company that specializes in addiction treatment. They developed and marketed Suboxone as a key product in the treatment of opioid addiction. The company's focus has been on providing medications and support for individuals struggling with addiction. Reckitt Benckiser Group is a multinational consumer goods company. They were the parent company of Indivior, Inc. before spinning it off as a separate entity. Reckitt Benckiser has already been involved in legal disputes with authorities, such as the FTC, over its marketing practices related to Suboxone, which led to significant legal actions and fines. This $30,000,000 class action settlement is unlikely to be the last class action or consumer protection news story.

Who Qualified for the Suboxone Settlement?

In order to qualify for the Suboxone Class Action Settlement you must file a class action claim on or before February 17, 2024. You must have paid for, or indirectly purchased Suboxone, or one of its "AB-rated" generic equivalent drugs at any time between December 22, 2011 and August 21, 2023. The purchase must have been made from either a pharmacy, or from a prescription via mail-order, and has to have been for consumption either for yourself, or for a family member. The following States qualify for location of purchase:

Qualifying State
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Oklahoma
Oregon
Pennsylvania
Puerto Rico
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
District of Columbia

How Much Could I Get in the Suboxone Settlement?

The total settlement amount is $30,000,000. The amount of payment per qualified claim will vary depending on the number of valid claim forms filed by the deadline of February 17, 2024. In 2021, for a previous FTC settlement and refund, each qualified consumer and patient was refunded an average payment of over $1,100. The total settlement fund was $59 Million. According to the FTC refund, the parent company of the manufacturer of Suboxone, allegedly took advantage of market forces in order to frighten consumers away from using the more affordable "AB-rated" generic Suboxone alternatives.

Free settlement alerts

Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.

Is This Settlement Still Open?

No. This settlement is closed — the claim deadline (February 17, 2024) has long passed, distribution checks were mailed on April 27, 2026, and the administrator's June 15, 2026 final cutoff for any documentation, check reissue requests, claim reviews, or adjustments has now passed as well. There is nothing left to file or request. For reference, the official settlement website remains at SuboxAntiTrust.com.

About This Page

OpenClassActions.com is only providing information and is not a class action administrator or a law firm. OpenClassActions is a participant in the Amazon affiliate advertising program and this post may contain affiliate links, which means we may earn a commission or fees if you make a purchase via those links.

For more class actions keep scrolling below.

Settlement Amount $30,000,000

Defendant Indivior, Inc.

Class Period December 22, 2011 – August 21, 2023

Status Closed — checks mailed Apr 27, 2026 June 15, 2026 final cutoff for adjustments has passed

Official Website SuboxAntiTrust.com